91�Թ�

A cannibalistic Mexican salamander that can regrow body parts lost in a fight may hold answers for researchers trying to unlock the power of stem cells to treat human disease, regenerative medicine pioneer Nadia Rosenthal told the inaugural symposium held at 91�Թ� this week.

“Everything develops, but not everything regenerates,” Rosenthal, scientific director at the in Maine, said as she described the Mexican axolotl’s unusual abilities, which have attracted the attention of scientists seeking to understand the basic mechanisms of regeneration.  

Rosenthal was among more than 250 engineering researchers, life scientists, computational biologists, doctors and students from across the 91�Թ� and affiliated hospitals who gathered at the on Nov. 28 to share research aimed at harnessing stem cells to treat conditions such as heart failure, cancer, liver disease and blindness.

The event, which also attracted a number of international experts in the field and representatives from the government and private sector, celebrated the first year of Medicine by Design, an initiative funded by a historic grant from the federal government’s that is driving stem cell research from foundational discovery to real-life application through innovative collaborations. 

“We are contributing something new by converging people from diverse disciplines – mathematics, the physical sciences, engineering, biology and medicine – around the big questions in regenerative medicine,” said Peter Zandstra, executive director of Medicine by Design, Canada Research Chair in stem cell bioengineering and a professor in the . 

Keith Pardee, an assistant professor in 91�Թ�'s Leslie Dan Faculty of Pharmacy and a Medicine by Design associate, introduces University Professor Molly Shoichet. Shoichet, a professor in 91�Թ�'s department of chemical engineering & applied chemistry, spoke about bioengineering strategies in regenerative medicine (photo by Neil Ta)

“It’s a really a very exciting time for regenerative medicine in Canada,” Zandstra added. “Medicine by Design, together with the , , the and a number of emerging regional clusters throughout the country, really represent a comprehensive innovation hub that will strengthen Canada as a leader in this emerging biotechnology sector.” 

Medicine by Design, which includes more than 90 principal investigators and hundreds of graduate students and postdoctoral fellows, builds on a rich legacy of 91�Թ� contributions to regenerative medicine, beginning with the demonstration of the existence of stem cells by biophysicist James Till and hematologist Ernest McCulloch in 1960.

In its first round of collaborative team project awards, announced in August 2016, Medicine by Design awarded a total of $27 million to 20 teams across 91�Թ� and its hospital partners for projects that range from basic exploration of stem cell biology to technology development and clinical application. The initiative is also strengthening Toronto’s network of regenerative medicine researchers by recruiting emerging and established leaders in the field, and is working closely with CCRM to commercialize the breakthroughs that emerge from its research. 

Read about the 20 teams chosen by Medicine by Design

“With our hospital and commercialization partners, we are building a robust pipeline from research to clinical translation to commercialization, which is moving discoveries more quickly from the lab bench to the bedside and catalyzing innovative ideas and approaches that will help us attract and retain the best people in the field,” said Vivek Goel, 91�Թ�’s vice-president of research and innovation.

Gordon Keller leads a Medicine by Design project that is working on using stem cells to grow functional liver cells and tissues that will enable researchers to study liver disease and test new drugs more easily. Keller, director of the McEwen Centre for Regenerative Medicine at University Health Network and a professor in 91�Թ�’s department of medical biophysics, credits the initiative with bringing together his diverse team, which has expertise in materials chemistry, tissue engineering, 3D bio-printing, liver transplantation and cystic fibrosis therapies.  

“The collaborative work we are doing would not have been possible without the strategic vision of Medicine by Design and the transformative investment by the ,” said Keller, Medicine by Design’s associate director of faculty recruitment

Keller has also successfully turned stem cells into different types of heart cells, and is working with CCRM to develop a technology to scale up the production of these heart cells for drug discovery and future use in the clinic.

PhD candidate Ashton Trotman-Grant, centre, discusses his poster with Medicine by Design symposium attendees. Trotman-Grant won the Blueline Therapeutic Translation Award for presenting the poster with the greatest commercialization potential (photo by Neil Ta)

Gary Bader, a professor at , is helming another Medicine by Design team project that is seeking to understand the most complicated computer of all: the human brain. Using the latest technologies for building molecular profiles of individual brain cells, the project will produce millions of data points that Bader’s team of biologists, physicists and mathematicians will use to look for ways to boost the brain’s natural ability to heal after a damage caused by stroke or injury.

Read more about the historic $114 million grant to Medicine by Design

The symposium also provided an opportunity for 20 graduate students and post-doctoral fellows working in the laboratories of Medicine by Design-funded principal investigators to present their research during a lunch-time poster session. Awards for the top three posters went to:

• Mina Ogawa, a research associate in Keller’s lab
• Peter Aldridge, a PhD candidate in the laboratory of Shana Kelley at the Institute of Biomaterials & Biomedical Engineering
• Siraj Zahr, a master’s candidate in the laboratory of Freda Miller at . 

Ashton Trotman-Grant, a PhD student in fundamental immunology in the laboratory of Juan Carlos Zúñiga-Pflücker at , won the , which recognized the poster with the greatest commercial translation potential. He is developing a cell-free technology that can be used to generate T cells from stem cells to treat cancer patients who become immunodeficient following therapy.

“The symposium was such an inspiring day for me,” said Trotman-Grant. “Listening to all the brilliant scientists speak about their work, you get a feeling that Canada is definitely emerging as a global leader in regenerative medicine.”

The inaugural Medicine by Design symposium attracted more than 250 researchers, students, and government and industry representatives (photo by Neil Ta)